Sleep spindles in bipolar disorder - a comparison to healthy control subjects

2018 ◽  
Vol 138 (2) ◽  
pp. 163-172 ◽  
Author(s):  
P. S. Ritter ◽  
J. Schwabedal ◽  
M. Brandt ◽  
W. Schrempf ◽  
F. Brezan ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Sleep Spindles ◽  
Control Subjects ◽  
Healthy Control

Magnetic resonance spectroscopic measurement of cerebral gamma-aminobutyric acid concentrations in patients with bipolar disorders

2006 ◽  
Vol 18 (2) ◽  
pp. 120-126 ◽  
Author(s):  
Po W. Wang ◽  
Napapon Sailasuta ◽  
Rebecca A. Chandler ◽  
Terence A. Ketter
Keyword(s):  
Bipolar Disorder ◽  
Magnetic Resonance ◽  
Mood Disorders ◽  
Bipolar Disorders ◽  
Occipital Lobe ◽  
Gabaergic Neurotransmission ◽  
Control Subjects ◽  
Bipolar Ii ◽  
Healthy Control ◽  
Cr Concentration

Background:Animal models of depression and psychopharmacological mechanisms of action suggest the importance of the gamma-amino butyric acid (GABA) system in the pathophysiology of mood disorders. Mood stabilizers have overlapping effects on GABAergic neurotransmission, and antidepressant use has been associated with alterations in GABAB receptor function. Magnetic resonance spectroscopy (MRS) provides an opportunity to noninvasively assess cerebral GABA concentrations in anterior paralimbic circuits that have been implicated in mood disorders.Methods:In bipolar disorder patients and healthy control subjects, we used MRS with a modified GABA-edited point resolved spectroscopy sequence (TE 68 ms, TR 1500 ms, 512 averages, total scan time 26 min) to assess GABA in an 18-cm3 occipital voxel. In addition, in another cohort of bipolar disorder patients and healthy control subjects, we similarly assessed GABA in a 12.5-cm3 medial prefrontal/anterior cingulate (MPF/AC) voxel. The concentration of GABA was referenced to creatine (Cr) from unedited spectra.Results:In bipolar patients and controls, we consistently detected 3.0 p.p.m. GABA peaks in occipital lobe and MPF/AC. In 16 bipolar (nine bipolar I and seven bipolar II) disorder patients, compared with six healthy control subjects, mean occipital GABA/Cr concentration was 61% higher. In addition, in 15 bipolar (five bipolar I, nine bipolar II, and one bipolar not otherwise specified) disorder patients, compared with six healthy control subjects, mean MPF/AC GABA/Cr concentration tended to be 41% higher.Conclusions:Patients with bipolar disorders may have increased cerebral GABA concentrations. Although this was more evident in the occipital lobe, MPC/AC GABA disturbance may be of greater potential interest in view the more established role of MPF/AC in affective processing. Additional studies are warranted to assess changes in GABAergic neurotransmission and the influences of diagnosis, mood state, and medication status in bipolar disorder patients.

O50. Correlation of plasma nitrite and nitrosoalbumin concentrations with body mass index in patients with bipolar disorder and healthy control subjects

Nitric Oxide ◽  
2008 ◽  
Vol 19 ◽  
pp. 31
Author(s):  
Mark D. Fossey ◽  
William T. Potter ◽  
Jessica Leon ◽  
William R. Yates ◽  
Andrew J. Gow
Keyword(s):  
Body Mass Index ◽  
Bipolar Disorder ◽  
Body Mass ◽  
Control Subjects ◽  
Healthy Control ◽  
Plasma Nitrite

An MRI study of adolescent patients with either schizophrenia or bipolar disorder as compared to healthy control subjects

1999 ◽  
Vol 46 (1) ◽  
pp. 78-88 ◽  
Author(s):  
Lee Friedman ◽  
Robert L Findling ◽  
John T Kenny ◽  
Thomas P Swales ◽  
Traci A Stuve ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Control Subjects ◽  
Adolescent Patients ◽  
Healthy Control ◽  
Mri Study

Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis

2013 ◽  
Vol 47 (9) ◽  
pp. 1119-1133 ◽  
Author(s):  
Klaus Munkholm ◽  
Julie Vestergaard Braüner ◽  
Lars Vedel Kessing ◽  
Maj Vinberg
Keyword(s):  
Systematic Review ◽  
Bipolar Disorder ◽  
Meta Analysis ◽  
Control Subjects ◽  
Healthy Control

A peripheral composite proteomic and gene expression biomarker related to diagnosis and affective state in rapid cycling bipolar disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S123-S123
Author(s):  
K. Munkholm ◽  
M. Vinberg ◽  
L.V. Kessing
Keyword(s):  
Gene Expression ◽  
Bipolar Disorder ◽  
Affective State ◽  
Biological Pathways ◽  
Clinical Test ◽  
Rapid Cycling ◽  
Affective States ◽  
Composite Measure ◽  
Control Subjects ◽  
Healthy Control

IntroductionManagement of bipolar disorder is limited by absence of laboratory test. While alterations related to multiple biological pathways have been found in bipolar disorder, findings have not translated into clinically applicable biomarkers. We previously found promise for a combined gene expression biomarker. The combination of gene expression and proteomic biomarkers could have potential as a meaningful clinical test.ObjectivesTo identify a composite biomarker based on multiple potential peripheral biomarkers related to neuroplasticity, inflammation and oxidative stress, both on a proteomic and gene expression level.AimsTo test the ability of a composite biomarker to discriminate between bipolar disorder patients and healthy control subjects and between affective states in bipolar disorder patients.MethodsmRNA expression of a set of 19 candidate genes and protein levels of immune markers and neurotrophic factors were measured in peripheral blood mononuclear cells and combined with urinary levels of oxidized nucleosides of 37 rapid cycling bipolar disorder patients in different affective states (depression, mania and euthymia) during a 6–12-month period and in 40 age- and gender-matched healthy control subjects. A composite measure was constructed in the first half of the sample and independently validated in the second half of the sample. The composite measure was evaluated using ROC curves and by calculating sensitivity and specificity.ResultsStatistical analysis is ongoing. Results will be presented at the congress.ConclusionsA peripheral composite biomarker based on multiple biological pathways on both proteomic and gene expression levels may have potential as a clinically applicable biomarker.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Altered Neurochemical Ingredient of Hippocampus in Patients with Bipolar Depression

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Murad Atmaca ◽  
Hanefi Yildirim
Keyword(s):  
Bipolar Disorder ◽  
Bipolar Depression ◽  
Hospital Staff ◽  
First Episode ◽  
Resonance Spectroscopy ◽  
Control Subjects ◽  
Healthy Control ◽  
Axis I ◽  
Dsm Iv ◽  
Lower Ratio

Background. In a number of investigations, hippocampal neurochemicals were evaluated in the patients with bipolar disorder who were on their first episode or euthymic periods. However, we did not meet any investigation in which only patients with bipolar depression were examined. As a consequence, the objective of the present study was to examine both sides of hippocampus of patients with bipolar disorder in depressive episode and healthy controls using1H-MRS.Methods. Thirteen patients with DSM-IV bipolar I disorder, most recent episode depressed, were recruited from the Department of Psychiatry at Firat University School of Medicine. We also studied 13 healthy comparison subjects who were without any DSM-IV Axis I disorders recruited from the hospital staff. The patients and controls underwent proton magnetic resonance spectroscopy (1H-MRS) of their hippocampus. NAA, CHO, and CRE values were measured.Results. No significant effect of diagnosis was observed for NAA/CRE ratio. For the NAA/CHO ratio, the ANCOVA with age, gender, and whole brain volume as covariates revealed that the patients with bipolar depression had significantly lower ratio compared to healthy control subjects for right and for left side. As for the CHO/CRE ratio, the difference was statistically significant for right side, with an effect diagnosis ofF= 4.763,P= 0.038, and was very nearly significant for left side, with an effect diagnosis ofF= 3.732,P= 0.064.Conclusions. We found that the patients with bipolar depression had lower NAA/CHO and higher CHO/CRE ratios compared to those of healthy control subjects. The findings of the present study also suggest that there may be a degenerative process concerning the hippocampus morphology in the patients with bipolar depression.

Pain perception in patients with bipolar disorder and schizophrenia

2007 ◽  
Vol 19 (5) ◽  
pp. 284-290 ◽  
Author(s):  
Levent Atik ◽  
Numan Konuk ◽  
Omer Akay ◽  
Devrim Ozturk ◽  
Ayten Erdogan
Keyword(s):  
Bipolar Disorder ◽  
Pain Perception ◽  
Cold Pressor Test ◽  
Bipolar Disorders ◽  
Cold Pressor ◽  
Study Groups ◽  
Pain Tolerance ◽  
Control Subjects ◽  
Lower Pain ◽  
Healthy Control

Objective:Pain perception is reported to be altered in patients with depression and schizophrenia. However, few studies have investigated the pain perception in patients with bipolar disorders. We therefore aimed to compare pain sensitivity between patients with bipolar disorder, schizophrenia and controls.Methods:Study groups consisted of 30 patients with bipolar disorder, and control groups consisted of 27 patients with schizophrenia and 59 healthy subjects. Pain perception was assessed with cold pressor test (CPT) by exposure to ice-water.Results:Patients with schizophrenia had significantly higher pain thresholds (PTh) than patients with bipolar disorder. There were no differences between the PTh of patients with schizophrenia and healthy control subjects. However, patients with bipolar disorder had significantly lower pain tolerance (PT) in the CPT than patients with schizophrenia and corresponding healthy control subjects.Conclusions:The higher PTh in the schizophrenia group compared with the bipolar group found in this study supports further investigation of a potential difference in the pain perception between patients with schizophrenia and bipolar disorder. Theoretical implications of these findings and possible relevant behavioural and neurochemical mechanisms are discussed.

Enhancement of Platelet Sensitivity to ADP-Aggregation by Isometric Exercise in Arteriosclerotic Patients and its Prevention

1977 ◽  
Vol 37 (02) ◽  
pp. 329-338 ◽  
Author(s):  
Tadahiro Sano ◽  
Takeshi Motomiya ◽  
Hiroh Yamazaki ◽  
Takio Shimamoto
Keyword(s):  
Cyclic Amp ◽  
Mechanical Stress ◽  
Optical Density ◽  
Platelet Function ◽  
Isometric Exercise ◽  
Phosphodiesterase Inhibitor ◽  
New Method ◽  
Platelet Aggregability ◽  
Control Subjects ◽  
Healthy Control

SummaryA new method for assessment of platelet sensitivity to ADP-aggregation was devised. Its reproducibility and the correlations between the values obtained by this method, the optical density (O. D.) method, and the screen filtration pressure (SFP) method were assessed. In summary, this method may be said to have three main points:1. It can be performed without centrifugation, avoiding mechanical stress to platelets, using only 0.8 ml. of blood and inexpensive equipment.2. It may reflect different aspects of platelet function from the O. D. method and the SFP method, despite the positive significant correlations between the values obtained by these three methods.3. It was proved to be highly reproducible and is thought to be useful clinically.By using this method, the effect of sustained isometric exercise by handgripping on platelet aggregability was assessed in coronary sclerotic and cerebral arteriosclerotic patients on placebo and EG-626, a newly synthesized cyclic AMP phosphodiesterase inhibitor. On placebo, an enhancement of platelet sensitivity was observed after isometric exercise in coronary and cerebral arteriosclerotic patients but not in healthy control subjects. The enhancement was prevented by pretreatment of EG-626, administered orally 1.5 hours prior to exercise.

Sign in / Sign up

Export Citation Format

Share Document